Compare · ABCL vs NVO
ABCL vs NVO
Side-by-side comparison of AbCellera Biologics Inc. (ABCL) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABCL and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.15B, about 127.4x ABCL ($1.50B).
- Over the past year, ABCL is up 58.9% and NVO is down 44.9% - ABCL leads by 103.8 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 4 for ABCL).
- NVO has more recent analyst coverage (25 ratings vs 17 for ABCL).
- Company
- AbCellera Biologics Inc.
- Novo Nordisk A/S
- Price
- $5.13+0.59%
- $43.39+1.40%
- Market cap
- $1.50B
- $191.15B
- 1M return
- +3.74%
- -7.66%
- 1Y return
- +58.91%
- -44.88%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 4
- 8
- Recent ratings
- 17
- 25
AbCellera Biologics Inc.
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, AI-powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. As of December 31, 2020, the company had 103 discovery programs that are either completed, in progress, or under contract. It has a discovery partnership agreement with Eli Lilly and Company. AbCellera Biologics Inc. was founded in 2012 and is headquartered in Vancouver, Canada.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ABCL
- AbCellera Biologics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- AbCellera Appoints Dr. Victor Sandor to its Board of Directors
- Chief Financial Officer Booth Andrew exercised 250,000 shares at a strike of $0.19, increasing direct ownership by 128% to 445,600 units (SEC Form 4)
- Director Montalbano John S. bought $95,400 worth of shares (20,000 units at $4.77), increasing direct ownership by 9% to 241,000 units (SEC Form 4)
- SEC Form 10-Q filed by AbCellera Biologics Inc.
- AbCellera Biologics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635
- Amendment: SEC Form SCHEDULE 13G/A filed by AbCellera Biologics Inc.
- AbCellera to Present at Upcoming Investor Conferences in May and June 2026
- Cantor Fitzgerald initiated coverage on AbCellera Biologics with a new price target
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care